Reliance on Partners’ Clinical Results, Policy Changes and Deteriorating Relationships
First written in FY2024. 4 of 6 entries say "Materialised", first in FY2025. Latest entry: 2026-08-14.
PRISM BioLab moved to the "Worse" side of this theme in 2025, 2 years after the typical company in this theme (2023).
The whole theme swung hardest in 2025: 3 of 9 companies on the "Worse" side.
4 other companies' latest entry also says "Materialised".
- FY2025MaterialisedAnnual report
「Although both companies had focused on joint research under the joint research agreement with Lilly and had achieved certain results, the agreement was terminated in September this year based on Lilly's strategic decision.」
The joint research agreement with Lilly was terminated based on a strategic decision, and the agreement with SERVIER was also terminated by mutual agreement in October 2025. The risk of a partner changing its policy or terminating an agreement actually materialized. - FY2024First statedAnnual report
「If the results of these trials are unfavorable or a good cooperative relationship with a partner can no longer be maintained, planned sales may decline and the expected future revenue may not be realized.」
The company explains that the clinical development progress of licensees affects milestone revenue and cash management.